Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy

British Journal of Cancer

Volumn 76, Issue 12, 1997, Pages 1636-1639

  Mainwaring, P N ^a   Nicolson, M C ^a   Hickish, T ^a   Penson, R ^b   Joel, S ^b   Slevin, M ^b   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Breast adenocarcinoma; Infusional; Non small cell lung carcinoma; Topotecan

Indexed keywords

TOPOTECAN;

ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALAISE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0030702834     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.609     Document Type: Article

References (19)

1. Burris HA, Rothenberg ML, Kuhn JG and Von Hoff DD (1992) Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19: 663-669
2. Chang AY, Garrow G, Boros L, Asbury R, Pandya K and Keng P (1995) Clinical and laboratory studies of topotecan in breast cancer. Proc Annu Meet Am Soc Clin Oncol 14: A118
3. Cheng MF, Chatterjee S and Berger NA (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269-279
4. Eckardt J, Burris H, Kuhn J, Smith S, Rodriguez G, Weiss C, Smith L, Shaffer D, Johnson R and Von Hoff D (1992) Phase I and pharmacokinetic trial of continuous infusion topotecan in patients with refractory solid tumours. Proc Annu Meet Am Soc Clin Oncal 11: A 373
5. Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE and Priest K (1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71: 366-370
6. Gehan E (1961) The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353
7. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ and Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12: 553-559
8. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chachoua A, Sorich J, Taubes B, Ludwig E and Broom C (1996) Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-l depletion (A NYGOG Study). Proc Eur Soc Med Oncol 21: 69
9. Hopwood P, Stephens RJ, Bleehen NM, Bolger JJ, Clark PI, Girling DJ, Hasleton PS, Macbeth FR, Machin D, Moghissi K, Saunders MI, Stephens RJ, Thatcher N and White RJ (1995) Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment. Br J Cancer 71: 633-636
10. National Cancer Institute (1981) Guidelines for Reporting Adverse Drug Reactions: National Cancer Institute, Division of Cancer Treatments: Bethesda, MD, USA
11. Lilenbaum RC and Green MR (1993) Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11: 1391-1402
12. Lynch T (1996) Topotecan today. J Clin Oncol 14: 3053-3055
13. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M and Frei E, III (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12: 347-352
14. Miller A, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
15. Perez Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN and Hong WK (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513
16. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH and Donehower RC ( 1992) Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656
17. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy JY, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F and Kelsen D (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85: 1499-1507
18. Verweij J, Lund B, Beijnen J, Planting A, De Boer DM, Koier J, Rosing H and Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673-678
19. Weitz JJ, Jung SH, Marschke RJ, Fitch TR and Jett JR (1995) Randomized Phase II trial of two schedules of Topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) Trial. Proc Annu Meet Am Soc Clin Oncol 14: A1053